


PRODUCT INFORMATION



ST1535

Item No. 10611

CAS Registry No.: 496955-42-1
Formal Name: 2-butyl-9-methyl-8-(2H-1,2,3-triazol-2-yl)-9H-purin-6-amine
MF: C₁₂H₁₆N₈
FW: 272.3
Purity: ≥98%
UV/Vis.: λ_{max}: 233, 290 nm
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

ST1535 is supplied as a solid. A stock solution may be made by dissolving the ST1535 in the solvent of choice, which should be purged with an inert gas. ST1535 is soluble in organic solvents such as DMSO and dimethyl formamide (DMF). The solubility of ST1535 in these solvents is approximately 5 mg/ml.

ST1535 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, ST1535 should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. ST1535 has a solubility of approximately 0.1 mg/ml in a 1:9 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

ST1535 is an adenosine A_{2A} receptor antagonist.¹ It is selective for adenosine A_{2A} over A₁ receptors (K_is = 2.3 and 107 nM, respectively, in radioligand binding assays). ST1535 inhibits agonist-induced production of cAMP in CHO cells expressing adenosine A_{2A} receptors (IC₅₀ = 353 nM). *In vivo*, ST1535 (10 and 20 mg/kg) reduces haloperidol-induced catalepsy in mice. It reduces the number of jaw tremors in a rat model of Parkinsonian jaw tremors induced by tacrine (Item No. 70240).² ST1535 (20 and 40 mg/kg) increases locomotor activity and reverses motor disabilities in a marmoset model of MPTP-induced Parkinson's disease.³

References

1. Stasi, M.A., Borsini, F., Varani, K., *et al.* ST 1535: A preferential A_{2A} adenosine receptor antagonist. *Int. J. Neuropsychopharmacol.* **9**(5), 575-584 (2006).
2. Tronci, E., Simola, N., Borsini, F., *et al.* Characterization of the antiparkinsonian effects of the new adenosine A_{2A} receptor antagonist ST1535: Acute and subchronic studies in rats. *Eur. J. Pharmacol.* **566**(1-3), 94-102 (2007).
3. Rose, S., Jackson, M.J., Smith, L.A., *et al.* The novel adenosine A_{2a} receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets. *Eur. J. Pharmacol.* **546**(1-3), 82-87 (2006).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/30/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM